Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President & CEO

See Remarks

Chief Commercial Officer

Chief Financial Officer

Chief Scientific Officer

Chief Operating Officer

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United State...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-09	Premium	gifted	Premium	Premium	Premium	-
2024-02-09	Premium	gifted	Premium	Premium	Premium	-
2024-02-01	Premium	acquired	Premium	Premium	Premium	-
2024-01-20	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2024-01-20	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-01-20	Premium	sold (taxes)	Premium	Premium	Premium	Chief Commercial Officer
2024-01-07	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-01-04	Premium	sold (taxes)	Premium	Premium	Premium	Chief Commercial Officer
2024-01-04	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2023-12-31	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-12-13	Premium	sold (taxes)	Premium	Premium	Premium	Chief Commercial Officer
2023-11-22	Premium	acquired	Premium	Premium	Premium	President & CEO
2023-11-22	Premium	sold	Premium	Premium	Premium	President & CEO
2023-04-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-04-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Commercial Officer
2023-03-31	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2023-01-20	Premium	acquired	Premium	Premium	Premium	President & CEO
2023-01-20	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-01-20	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-01-20	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-01-11	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2023-01-10	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2023-01-07	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2023-01-04	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2023-01-04	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer

CHRS - Coherus Biosciences Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CHRS